Preclinical Testing of Integrin Enhancing Molecules for the Treatment of Muscular
整合素增强分子治疗肌肉萎缩症的临床前测试
基本信息
- 批准号:7970910
- 负责人:
- 金额:$ 19.04万
- 依托单位:
- 依托单位国家:美国
- 项目类别:
- 财政年份:2010
- 资助国家:美国
- 起止时间:2010-08-18 至 2012-05-31
- 项目状态:已结题
- 来源:
- 关键词:AffectBindingBiological AssayBiomedical ResearchCellsCessation of lifeChildClinical TrialsComplexDataDeteriorationDevelopmentDilated CardiomyopathyDiseaseDisease ProgressionDoseDuchenne muscular dystrophyDystrophinEchocardiographyEuropean UnionExerciseFDA approvedFibrosisFutureGene ExpressionGenesGlycoproteinsHumanInflammationInjuryIntegrinsInterventionLamininLaminin ReceptorLeadLongevityMeasuresMusMuscleMuscle CellsMuscle functionMuscular DystrophiesMutationMyocardiumMyopathyNeuromuscular DiseasesPathologyPatientsPharmaceutical PreparationsPreclinical TestingPredispositionProteinsReverse Transcriptase Polymerase Chain ReactionSkeletal MuscleSmall Animal Imaging SystemsTechnologyTestingTherapeuticTransgenic OrganismsTranslatingUnited StatesWasting Syndromebasedrug developmentdrug discoveryeffective therapygraspimprovedmdx mousemouse modelmuscle regenerationmuscular dystrophy mouse modelnovelpreclinical studyprematurepreventpromoterpublic health relevanceskeletal
项目摘要
DESCRIPTION (provided by applicant): Duchenne Muscular Dystrophy (DMD) is a lethal muscle wasting disease for which there is currently no cure or effective treatment. DMD is caused by mutations in the gene encoding dystrophin resulting in an absence of the dystrophin protein, a critical component of the laminin binding dystrophin glycoprotein complex in muscle. Loss of dystrophin results in reduced sarcolemmal integrity and increased susceptibility to muscle damage. The 1721 integrin is also a major laminin receptor in muscle that is increased in DMD patients and the mdx mouse model. These observations led to the hypothesis that the 1721 integrin is a major modifier of disease progression in DMD. In support of this idea, transgenic over-expression of the 17 integrin in muscle alleviates muscle disease in dystrophic mice, while loss of 17 integrin in dystrophic muscle results in more severe disease. Together these results indicate pharmacological interventions which promote increased 17 integrin expression in muscle may be an effective therapeutic approach for the treatment of DMD. Recently, using a novel muscle cell-based assay and drug discovery technology, we have identified several compounds that increase 17 integrin expression in cultured muscle cells. In this study we will initiate preclinical testing of these compounds in mouse models of DMD. Our studies will determine the optimal dose of these compounds and determine if they increase longevity and prevent muscle disease progression in DMD mouse models. Compounds will also be tested to determine if they prevent the development of dilated cardiomyopathy associated with muscular dystrophy using echocardiography and if they prevent deterioration in muscle function. Together these aims will allow us to test the hypothesis that compounds which increase 17 integrin gene expression can prevent muscle disease progression in mouse models of DMD. The identification of compounds that increase 17 integrin expression and prevent muscle disease in mouse models of DMD will form the basis of future studies that will translate our basic biomedical research into the development of drugs for clinical trials for DMD.
PUBLIC HEALTH RELEVANCE: Duchenne Muscular Dystrophy (DMD) is a devastating muscle disease that affects nearly 50,000 children in the United States and European Union. Increased expression of 17 integrin has been shown to be enormously beneficial in DMD mouse models. This study aims to conduct preclinical testing of novel drugs that enhanced 17 integrin expression in muscle to determine if they maybe of therapeutic value to DMD patients.
描述(由申请人提供):杜氏肌营养不良症(DMD)是一种致命的肌肉萎缩性疾病,目前没有治愈或有效的治疗方法。DMD是由编码肌营养不良蛋白的基因突变引起的,导致肌营养不良蛋白的缺失,肌营养不良蛋白是肌肉中层粘连蛋白结合肌营养不良蛋白糖蛋白复合物的关键组分。肌营养不良蛋白的缺失导致肌膜完整性降低和对肌肉损伤的易感性增加。1721整合素也是肌肉中的主要层粘连蛋白受体,其在DMD患者和mdx小鼠模型中增加。这些观察结果导致了这样的假设:1721整联蛋白是DMD疾病进展的主要调节因素。为了支持这一观点,肌肉中17整合素的转基因过表达加重了营养不良小鼠的肌肉疾病,而营养不良肌肉中17整合素的缺失导致更严重的疾病。这些结果共同表明,促进肌肉中整合素表达增加的药理学干预可能是治疗DMD的有效治疗方法。最近,使用一种新的基于肌细胞的测定和药物发现技术,我们已经确定了几种化合物,增加17整合素在培养的肌细胞中的表达。在这项研究中,我们将在DMD小鼠模型中开始这些化合物的临床前试验。我们的研究将确定这些化合物的最佳剂量,并确定它们是否能延长DMD小鼠模型的寿命并预防肌肉疾病的进展。化合物也将进行测试,以确定他们是否防止发展扩张型心肌病与肌肉萎缩症使用超声心动图,如果他们防止肌肉功能恶化。这些目标将使我们能够检验增加17整合素基因表达的化合物可以预防DMD小鼠模型中肌肉疾病进展的假设。在DMD小鼠模型中识别增加17整合素表达并预防肌肉疾病的化合物将成为未来研究的基础,这些研究将把我们的基础生物医学研究转化为DMD临床试验药物的开发。
公共卫生关系:杜氏肌营养不良症(DMD)是一种毁灭性的肌肉疾病,影响着美国和欧盟近5万名儿童。17整合素的表达增加已显示在DMD小鼠模型中是非常有益的。本研究的目的是进行临床前试验的新药,提高17整合素在肌肉中的表达,以确定他们是否可能对DMD患者的治疗价值。
项目成果
期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
数据更新时间:{{ journalArticles.updateTime }}
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
数据更新时间:{{ journalArticles.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ monograph.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ sciAawards.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ conferencePapers.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ patent.updateTime }}
DEAN J. BURKIN其他文献
DEAN J. BURKIN的其他文献
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
{{ truncateString('DEAN J. BURKIN', 18)}}的其他基金
Optimization of an integrin enhancing molecule for the treatment of Duchenne muscular dystrophy
用于治疗杜氏肌营养不良症的整合素增强分子的优化
- 批准号:
10010445 - 财政年份:2015
- 资助金额:
$ 19.04万 - 项目类别:
Optimization of an integrin enhancing molecule for the treatment of Duchenne muscular dystrophy
用于治疗杜氏肌营养不良症的整合素增强分子的优化
- 批准号:
10246962 - 财政年份:2015
- 资助金额:
$ 19.04万 - 项目类别:
Laminin protein therapy for Congenital Muscular Dystrophy
层粘连蛋白治疗先天性肌营养不良症
- 批准号:
8697998 - 财政年份:2014
- 资助金额:
$ 19.04万 - 项目类别:
Galectin 1: A novel small protein therapy for Duchenne muscular dystrophy
半乳糖凝集素 1:一种治疗杜氏肌营养不良症的新型小蛋白疗法
- 批准号:
9104670 - 财政年份:2014
- 资助金额:
$ 19.04万 - 项目类别:
Galectin 1: A novel small protein therapy for Duchenne muscular dystrophy
半乳糖凝集素 1:一种治疗杜氏肌营养不良症的新型小蛋白疗法
- 批准号:
8781546 - 财政年份:2014
- 资助金额:
$ 19.04万 - 项目类别:
Laminin protein therapy for Congenital Muscular Dystrophy
层粘连蛋白治疗先天性肌营养不良症
- 批准号:
8877405 - 财政年份:2014
- 资助金额:
$ 19.04万 - 项目类别:
Congenital Muscular Dystrophy: From Clinical Pathology to Underlying Scientific M
先天性肌营养不良症:从临床病理学到基础科学 M
- 批准号:
8319246 - 财政年份:2012
- 资助金额:
$ 19.04万 - 项目类别:
Preclinical Testing of Integrin Enhancing Molecules for the Treatment of Muscular
整合素增强分子治疗肌肉萎缩症的临床前测试
- 批准号:
8131058 - 财政年份:2010
- 资助金额:
$ 19.04万 - 项目类别:
COBRE: UNV MED SCH: P1: INTEGRIN REGULATION OF VASCULAR SMOOTH MUSCLE
COBRE:UNV MED SCH:P1:血管平滑肌的整合素调节
- 批准号:
7960564 - 财政年份:2009
- 资助金额:
$ 19.04万 - 项目类别:
COBRE: UNR: TARGETED & TRANSGENIC ANIMAL CORE (A): ES CELLS
COBRE:UNR:有针对性
- 批准号:
7959484 - 财政年份:2009
- 资助金额:
$ 19.04万 - 项目类别:
相似国自然基金
帽结合蛋白(cap binding protein)调控乙烯信号转导的分子机制
- 批准号:32170319
- 批准年份:2021
- 资助金额:58.00 万元
- 项目类别:面上项目
帽结合蛋白(cap binding protein)调控乙烯信号转导的分子机制
- 批准号:
- 批准年份:2021
- 资助金额:58 万元
- 项目类别:
ID1 (Inhibitor of DNA binding 1) 在口蹄疫病毒感染中作用机制的研究
- 批准号:31672538
- 批准年份:2016
- 资助金额:62.0 万元
- 项目类别:面上项目
番茄EIN3-binding F-box蛋白2超表达诱导单性结实和果实成熟异常的机制研究
- 批准号:31372080
- 批准年份:2013
- 资助金额:80.0 万元
- 项目类别:面上项目
P53 binding protein 1 调控乳腺癌进展转移及化疗敏感性的机制研究
- 批准号:81172529
- 批准年份:2011
- 资助金额:58.0 万元
- 项目类别:面上项目
DBP(Vitamin D Binding Protein)在多发性硬化中的作用和相关机制的蛋白质组学研究
- 批准号:81070952
- 批准年份:2010
- 资助金额:35.0 万元
- 项目类别:面上项目
研究EB1(End-Binding protein 1)的癌基因特性及作用机制
- 批准号:30672361
- 批准年份:2006
- 资助金额:24.0 万元
- 项目类别:面上项目
相似海外基金
Collaborative Research: NSF-BSF: How cell adhesion molecules control neuronal circuit wiring: Binding affinities, binding availability and sub-cellular localization
合作研究:NSF-BSF:细胞粘附分子如何控制神经元电路布线:结合亲和力、结合可用性和亚细胞定位
- 批准号:
2321481 - 财政年份:2024
- 资助金额:
$ 19.04万 - 项目类别:
Continuing Grant
Collaborative Research: NSF-BSF: How cell adhesion molecules control neuronal circuit wiring: Binding affinities, binding availability and sub-cellular localization
合作研究:NSF-BSF:细胞粘附分子如何控制神经元电路布线:结合亲和力、结合可用性和亚细胞定位
- 批准号:
2321480 - 财政年份:2024
- 资助金额:
$ 19.04万 - 项目类别:
Continuing Grant
Alkane transformations through binding to metals
通过与金属结合进行烷烃转化
- 批准号:
DP240103289 - 财政年份:2024
- 资助金额:
$ 19.04万 - 项目类别:
Discovery Projects
NPBactID - Differential binding of peptoid functionalized nanoparticles to bacteria for identifying specific strains
NPBactID - 类肽功能化纳米粒子与细菌的差异结合,用于识别特定菌株
- 批准号:
EP/Y029542/1 - 财政年份:2024
- 资助金额:
$ 19.04万 - 项目类别:
Fellowship
Conformations of musk odorants and their binding to human musk receptors
麝香气味剂的构象及其与人类麝香受体的结合
- 批准号:
EP/X039420/1 - 财政年份:2024
- 资助金额:
$ 19.04万 - 项目类别:
Research Grant
Postdoctoral Fellowship: OPP-PRF: Understanding the Role of Specific Iron-binding Organic Ligands in Governing Iron Biogeochemistry in the Southern Ocean
博士后奖学金:OPP-PRF:了解特定铁结合有机配体在控制南大洋铁生物地球化学中的作用
- 批准号:
2317664 - 财政年份:2024
- 资助金额:
$ 19.04万 - 项目类别:
Standard Grant
I-Corps: Translation Potential of Real-time, Ultrasensitive Electrical Transduction of Biological Binding Events for Pathogen and Disease Detection
I-Corps:生物结合事件的实时、超灵敏电转导在病原体和疾病检测中的转化潜力
- 批准号:
2419915 - 财政年份:2024
- 资助金额:
$ 19.04万 - 项目类别:
Standard Grant
CRII: OAC: Development of a modular framework for the modeling of peptide and protein binding to membranes
CRII:OAC:开发用于模拟肽和蛋白质与膜结合的模块化框架
- 批准号:
2347997 - 财政年份:2024
- 资助金额:
$ 19.04万 - 项目类别:
Standard Grant
How lipid binding proteins shape the activity of nuclear hormone receptors
脂质结合蛋白如何影响核激素受体的活性
- 批准号:
DP240103141 - 财政年份:2024
- 资助金额:
$ 19.04万 - 项目类别:
Discovery Projects
The roles of a universally conserved DNA-and RNA-binding domain in controlling MRSA virulence and antibiotic resistance
普遍保守的 DNA 和 RNA 结合域在控制 MRSA 毒力和抗生素耐药性中的作用
- 批准号:
MR/Y013131/1 - 财政年份:2024
- 资助金额:
$ 19.04万 - 项目类别:
Research Grant